[New radiopharmaceuticals for oncologic diagnosis and therapy: developments in radioimmunoscintigraphy and radioimmunotherapy].
131I labeled monoclonal antibodies are at a disadvantage for radioimmunoscintigraphy due to the in-vivo cleavage of radioiodine by deiodases. Alternative labeling with 99mTc was not very successful because of the lack of suitable ligands for stable technetium complexes. New developments in this field will be presented using stable 99mTc-N2S2 complexes. Some comments on radioimmunotherapy have also been added.